Mediar Therapeutics

Mediar Therapeutics

  • Founded: 2018
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Fibrosis
  • Drug types: LNG, HEP
  • Lead product: Undisclosed
  • Product link:
  • Funding: $85M A Mar 2023; $20M prior to Mar 2023
  • Investors: Novartis Venture Fund, Sofinnova Partners, Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment, Mass General Brigham Ventures

job board

Short description:

Contact us to add description:

Drug notes:

2 additional undisclosed programs RD/Clin0 fibrosis

Long description:

Mediar Therapeutics is a pre-clinical stage biotech company in Cambridge, MA, developing treatments that target fibrotic mediators that drive disease progression. This novel approach addresses the underlying mechanisms behind fibrosis, a condition that causes the scarring of organs and tissues. This is different from traditional approaches that focus on initiators of fibrosis that may cause adverse effects to inflammatory pathways. They aim to address late-stage fibrosis, a condition with little to no current treatment options. Their team’s expertise in antibody engineering is helping accelerate treatments for halting or reversing fibrosis to the clinic. Mediar was founded in 2019 by current CSO, Paul Yaworsky, who previously spent over 20 years in drug discovery and development at Pfizer.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy